文献速递糖尿病

2型糖尿病患者HbA1c正常化可改善神经病变结局

Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2018-11-19

本研究在38例血糖控制不佳的2型糖尿病患者中,比较强化HbA1c控制(EHC)与常规血糖控制对神经病变结局指标的影响。结果显示,EHC使HbA1c正常化并改善神经生理和角膜神经纤维指标至糖耐量受损水平,而常规控制仅改善振动觉;白蛋白排泄率显著下降,但视网膜病变无显著改善。

要点

  • EHC使HbA1c正常化可改善神经病变结局指标至IGT水平
  • 常规血糖控制仅改善振动觉,未改善其他神经指标
  • EHC显著降低白蛋白排泄率,但视网膜病变无显著改善

核心结论

  • 短期2型糖尿病患者通过EHC使HbA1c正常化,改善神经病变和肾病等微血管并发症优于标准血糖控制,但视网膜病变无改善。

研究设计与样本

  • 研究纳入38例血糖控制不佳的2型糖尿病患者(基线HbA1c 9.6% [81.4 mmol/mol]),进行4年饮食限制和降糖药治疗伴或不伴EHC,并与48例正常糖耐量受试者和34例IGT受试者(仅基线)比较。

主要发现

  • EHC队列4.3年和最后2年HbA1c分别改善至6.1% (43.2 mmol/mol)和5.8% (39.9 mmol/mol),体重减少7.3 kg,50%和28.9%患者分别恢复至IGT和NGT。
  • EHC使神经生理和角膜神经纤维指标改善至与IGT相似,而常规血糖控制(平均HbA1c 7.0% [53.5 mmol/mol])仅改善振动觉。
  • 高血糖变异性(GV)和基线HbA1c水平损害神经病变结局指标的改善。
  • EHC组白蛋白排泄率显著下降,视网膜病变严重程度和频率无显著恶化。

临床怎么用

  • 对短期2型糖尿病患者,强化血糖控制使HbA1c正常化可能更有效改善神经病变和肾病,但需注意视网膜病变无显著获益。

局限性

  • 样本量较小(EHC组38例),对照组仅基线数据,随访4年,视网膜病变变化无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of normalizing HbA1c by extensive HbA1c control (EHC) on neuropathy outcome measures (NOMs), nephropathy, and retinopathy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Detailed clinical and neurological examinations were performed in two cohorts of 38 patients with uncontrolled type 2 diabetes (HbA1c 9.6% [81.4 mmol/mol]) at baseline and after glycemic control (GC) with or without EHC by diet restriction and hypoglycemic agents over 4 years along with 48 control subjects with normal glucose tolerance (NGT) and 34 subjects with impaired glucose tolerance (IGT) only at baseline. EHC patients, control subjects, and subjects with IGT underwent oral glucose tolerance tests. Glycemic variability (GV) was evaluated by SD and coefficient of variation of monthly measured HbA1c levels and casual plasma glucose. RESULTS: In the EHC cohort, HbA1c levels over 4.3 years and the last 2 years improved to 6.1% (43.2 mmol/mol) and 5.8% (39.9 mmol/mol) with 7.3 kg body wt reduction, and 50% and 28.9% of patients returned to IGT and NGT, respectively, at end point. Baseline neurophysiological and corneal nerve fiber (CNF) measures were impaired in patients. Normalized HbA1c with EHC improved neurophysiological and CNF measures to be similar for those for IGT, while GC without EHC (mean HbA1c level 7.0% [53.5 mmol/mol]) improved only vibration perception. The mean normalized HbA1c levels by EHC determined NOM improvements. The high GV and baseline HbA1c levels compromised NOMs. Albumin excretion rate significantly decreased, while retinopathy severity and frequency insignificantly worsened on EHC. CONCLUSIONS: Normalizing HbA1c in type 2 diabetes of short duration improves microvascular complications including neuropathy and nephropathy more effectively than standard GC but not retinopathy.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ishibashi F, Taniguchi M, Kosaka A, et al. Improvement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes. Diabetes Care. 2018. PMID: 30455338. doi:10.2337/dc18-1560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。